Table 3.
Liver-Specific characteristics of HIV-infected participants by HBV infection status (N = 2419)
| Clinical Characteristics | HIV N = 2220 | HIV-HBV Co-Infected N = 199 | p valuea |
|---|---|---|---|
| Hepatitis C co-infection | 520 (23) | 61 (31) | 0.02 |
| Baseline AST (IU/L) | 29 (23–41) | 36 (26–62) | < 0.0001 |
| Baseline AST category | |||
| Normal (10–40 IU/L) | 1649 (74) | 120 (60) | < 0.0001 |
| Elevated (> 40 IU/L) | 571 (26) | 79 (40) | |
| End of follow-up AST | 25 (20–33) | 26 (20–38) | 0.14 |
| End of follow-up AST category | |||
| Normal (10–40 IU/L) | 1855 (84) | 152 (76) | 0.01 |
| Elevated (> 40 IU/L) | 365 (17) | 47 (24) | |
| Baseline APRI | 0.37 (0.27–0.59) | 0.50 (0.35–1.04) | < 0.0001 |
| Baseline APRI Fibrosis category | |||
| ≤ 0.5 (minimal) | 1501 (68) | 99 (50) | < 0.0001b |
| 0.51–1.49 (moderate) | 593 (27) | 68 (34) | |
| 1.50–1.99 (significant) | 34 (2) | 8 (4) | |
| ≥ 2.0 (advanced/cirrhosis) | 92 (4) | 24 (12) | |
| End of follow-up APRI | 0.30 (0.22–0.43) | 0.32 (0.23–0.56) | 0.03 |
| End of follow-up APRI Fibrosis category | |||
| ≤ 0.5 (minimal) | 1831 (82) | 145 (73) | 0.005b |
| 0.51–1.49 (moderate) | 302 (14) | 39 (20) | |
| 1.50–1.99 (significant) | 24 (1) | 3 (2) | |
| ≥ 2.0 (advanced/cirrhosis) | 63 (3) | 12 (6) | |
AST aspartate aminotransferase, APRI aspartate aminotransferase to platelet ratio index, VS virological suppression, FARVDT first naïve ARV date
aData shown are frequencies and proportions for categorical variables and median and interquartile ranges for continuous variables. p values for continuous variables were calculated using chi-square or Fisher exact tests and for continuous variables were calculated using Wilcoxon’s Rank Sum tests
bp values were calculated using Kruskal-Wallis rank tests